These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 29631670)
1. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs? Altmann KH Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670 [No Abstract] [Full Text] [Related]
2. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. Cazzamalli S; Corso AD; Neri D J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855 [TBL] [Abstract][Full Text] [Related]
3. Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S; Dal Corso A; Widmayer F; Neri D J Am Chem Soc; 2018 Feb; 140(5):1617-1621. PubMed ID: 29342352 [TBL] [Abstract][Full Text] [Related]
4. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers. Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036 [TBL] [Abstract][Full Text] [Related]
5. Targeting carbonic anhydrase IX with small organic ligands. Wichert M; Krall N Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398 [TBL] [Abstract][Full Text] [Related]
6. Effect of attachment site on stability of cleavable antibody drug conjugates. Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134 [TBL] [Abstract][Full Text] [Related]
7. Sequence-Defined Oligoamide Drug Conjugates of Pretubulysin and Methotrexate for Folate Receptor Targeted Cancer Therapy. Truebenbach I; Gorges J; Kuhn J; Kern S; Baratti E; Kazmaier U; Wagner E; Lächelt U Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28371444 [TBL] [Abstract][Full Text] [Related]
8. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo. Krall N; Pretto F; Mattarella M; Müller C; Neri D J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427 [TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754 [TBL] [Abstract][Full Text] [Related]
10. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. Beerli RR; Hell T; Merkel AS; Grawunder U PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162 [TBL] [Abstract][Full Text] [Related]
12. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944 [TBL] [Abstract][Full Text] [Related]
13. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2. Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298 [No Abstract] [Full Text] [Related]
14. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Ahlskog JK; Dumelin CE; Trüssel S; Mårlind J; Neri D Bioorg Med Chem Lett; 2009 Aug; 19(16):4851-6. PubMed ID: 19615903 [TBL] [Abstract][Full Text] [Related]
15. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer. Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613 [TBL] [Abstract][Full Text] [Related]
16. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment. Paulus J; Sewald N J Pept Sci; 2024 Jul; 30(7):e3561. PubMed ID: 38382900 [TBL] [Abstract][Full Text] [Related]
17. Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins. Marshall DJ; Harried SS; Murphy JL; Hall CA; Shekhani MS; Pain C; Lyons CA; Chillemi A; Malavasi F; Pearce HL; Thorson JS; Prudent JR Mol Ther; 2016 Oct; 24(10):1760-1770. PubMed ID: 27434591 [TBL] [Abstract][Full Text] [Related]
19. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Bryant JL; Gieling RG; Meredith SL; Allen TJ; Walker L; Telfer BA; Supuran CT; Williams KJ; White A Int J Cancer; 2018 Jan; 142(1):191-201. PubMed ID: 28905987 [TBL] [Abstract][Full Text] [Related]
20. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]